I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
Published in: Blood Advances
Janneke W de Boer, Elise R A Pennings, Ankie Kleinjan,
Jaap A van Doesum, Anne M Spanjaart, Pim G N J Mutsaers, Margot Jak, Marjolein W M van der Poel, Maria T Kuipers, Judit A Adam,
Arjan Diepstra, Lianne Koens, Suzanne van Dorp, Joost S P Vermaat,
Anne G H Niezink, Marie José Kersten,
Tom van Meerten
MO-0960 Evaluating semi-automated 18F-FDG PET segmentation methods to predict Large B-cell lymphoma outcomes
Published in: Radiotherapy and Oncology
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
Published in: JCO oncology practice
PURPOSE:Prompt recognition of acute chimeric antigen receptor T (CAR T)-cell-mediated toxicities is crucial because adequate and timely management can prevent or reverse potential life-threatening complications. In the outpatient setting, patients and informal caregivers have to recognize and report signs and symptoms marking these acute toxicities. This study provides a core set of patient- and caregiver-reported signs and symptoms (outcomes, P/CROs) and definitions of red flags warranting immediate action to include in a daily checklist for support at home, with the goal to make outpatient post-CAR T-cell care safer,...
Anne M. Spanjaart, Elise R.A. Pennings, Milan Kos, Pim G.N.J. Mutsaers, Pieternella J. Lugtenburg,
Tom Van Meerten,
Jaap A. Van Doesum, Monique C. Minnema, Margot Jak, Suzanne Van Dorp, Joost S.P. Vermaat, Marjolein W.M. Van Der Poel, Martijn G.H. Van Oijen, Maria T. Kuipers, Inger S. Nijhof, Marie José Kersten
High frequency of hyperglycaemia observed during CAR T-cell treatment
Published in: Diabetic Medicine
Semi-automated 18F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation
Published in: Computational and Structural Biotechnology Journal
In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be a prognostic factor in NHL. It is usually retrieved using semi-automated thresholding methods based on standardized uptake values (SUV), calculated from 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) images. However, there is currently no consensus method for NHL. The aim of this study was to review literature on different segmentation methods used, and to evaluate selected methods by using...
